Novartis launches Jakavi in 50+ countries; J&J to market hep C drug in Europe;

> Novartis ($NVS) has launched myelofibrosis drug Jakavi in Singapore and 50 other countries. Report

> Johnson & Johnson's ($JNJ) Janssen has won EU marketing authorization for hep C drug Olysio. Release

> Tolmar Pharma has regained marketing rights for prostate cancer drug Eligard in the U.S. and Puerto Rico. More

> A new report highlights the meningococcal vaccines market through 2019. Release

And Finally... Some tech companies are betting that sifting through patients' social media posts will yield critical side-effect insights that drugmakers will buy. More

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.